[Chemo-endocrine therapy of advanced breast cancer].
There have been few randomized trials that have shown a significantly longer survival after chemo-endocrine therapy than the chemotherapy or the endocrine therapy alone, although there seem to be rationales for simultaneous combination of the both modalities. Some new strategies that would make the response rate higher as well as obtain a longer survival by means of chemo-endocrine therapy was suggested. At the present time, sequential endocrine therapy to chemotherapy is recommended for the advanced or recurrent breast cancer patients, except for those with larger tumor burden, liver metastasis, rapid growing tumors, and ER-negative tumors.
Nomura
Y
Y
Dept. of Breast Surgery, National Kyushu Cancer Center Hospital, Fukuoka, Japan.
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000601:surgery; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D008525:Medroxyprogesterone / Q000031:analogs & derivatives / Q000627:therapeutic use; D017258:Medroxyprogesterone Acetate; D010052:Ovariectomy; D013629:Tamoxifen / Q000627:therapeutic use*
D013629:Tamoxifen; D017258:Medroxyprogesterone Acetate; D008525:Medroxyprogesterone